Klick Health execs say technology is key to strategic and creative brand building, keeping up with clients, remaining relevant – and in business TORONTO, ON/NEW YORK, NY – June 15, […]
The rapid study startup process can ensure studies are finely tuned for scientific validity.
The Greater Than One Group (GTO), the leading independent digital communications company, announced the addition of Kieran Walsh as Global Account Director.
Incentives, Opportunities Abound as Orphan Drug Demand Grows
Biopharma, Bones, Breakthrough Therapy Designation, CDC, Congress, Department of Health and Human Services (HHS), EMA, Enzyme Replacement, EU, FDA, FDA/Regulatory, glioblastoma Multiforme (GBM) Brain Cancer, Hypophosphatasia (HPP), June 2017, Metabolic Disorders, Orphan Drug Act, Rare DiseasesConcerted effort by governments, regulators, and industry is rapidly expanding development of new therapies for the more than 7,000 known rare diseases.
Concentric Health Experience Names Three New SVP, Client Services Directors in Response to Record-Breaking 2016.
2016 Annual Report: State Of The Bio Industry
Acute Myeloid Leukemia (AML), Analysts, Approvals, Biliary Atresia, Biopharma, Biotech, Biotech/Biopharma, Biotechnology, Checkpoint Inhibitors, Farnesoid X Receptor (FXR) Agonists, Forecasts, Immune System, Immune Systems, Immuno-oncology, Issue Archives, June 2016, Liver Disease, M&A, M&A, Nonalcoholic Steatohepatitis (NASH), PD-1/PD-L1 inhibitors, PD-L1 Inhibitor, Potential Blockbusters, Pricing, Primary Sclerosing Cholangitis (PSC), Special Reports, T-CellsThe outlook remains bright due to a favorable regulatory arena, support for biopharma-friendly legislation and development incentives, expanding scientific opportunities in key therapeutic areas such as immuno-oncology, and big pharma’s continued push to obtain innovation.
In mid-May, pharma giant Pfizer agreed to buy Anacor Pharmaceuticals for a total transaction value, net of cash, of $5.2 billion. Anacor is a biopharmaceutical company concentrated on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform.
Researchers revealed the first U.S. case of a pathogen carrying a mutated strain of E. coli resistant to an antibiotic used as a final defense versus superbugs. As a result, there has been heightened concern that a post-antibiotic era will arrive earlier than predicted.
Emerging therapeutic company investment and deal trends
Biopharma, Biotech, Biotech/Biopharma, Biotechnology, Biotechnology Innovation Organization (BIO), Financing, Follow-On Public Offerings (FOPOs_, Initial Public Offering (IPO), Innovation, IPO, IPOs, Issue Archives, June 2016, M&A, M&A, R&D, Series A Preferred Stock, Venture CapitalThe Biotechnology Industry Organization released a report titled: Emerging Therapeutic Company Investment and Deal Trends. BIO Industry Analysis says more than 90 percent of the biopharma industry is composed of small, emerging companies. According to BIO President Jim Greenwood and E. Cartier Esham, Ph.D., executive VP of BIO’s Emerging Companies Section, it is important for the trade association to better understand early-stage investor and deal-making trends in order to determine where scientific or policy issues may be affecting the ability to maintain a robust pipeline of innovative medicines.
Projected blockbuster bio products with potential launches in 2016
Atopic Dermatitis, Bladder, Bladder Cancer, Clinical Trials, Immunotherapies, Issue Archives, June 2016, Launches, Multiple Sclerosis, PD-1/PD-L1 inhibitors, PD-L1 Inhibitor, Potential Blockbusters, Product Launches, Prostacyclin Receptor Agonists, Pulmonary Arterial Hypertension, R&D, Relapsing Multiple Sclerosis (RMS)Dupilumab, Regeneron/Sanofi Dupilumab is the first systemic therapy to demonstrate positive Phase III results in patients with moderate-to-severe atopic dermatitis. The serious, chronic inflammatory skin disease is marked by widespread […]